AMLX: Amylyx Pharmaceuticals, Inc.
Performance
AMLX +145.41%
Watchlist
Select an item
Summary
AMLX at a glance
AMLX returned +145.41% over the past year. Its worst drop in that year was -33.59%, smaller than 50% of stocks on Redstone, and its Sharpe ratio of 1.36 beats 88% of stocks on Redstone. It pays no dividends.
Current Drawdown
-23.83%
Rolling Volatility
54.13%
Actions
Metrics
Risk Indicators
Alpha108.48%
Beta0.97x
Sharpe1.36
Sortino3.26
Omega1.35
Calmar4.33
Martin6.94
Profile
About AMLX
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $3.8B
- Listed
- Jan 2022
- Employees
- 136
- Headquarters
- Cambridge, MA
- Website
- amylyx.com
Comparisons